Wuxi AppTec joins biologics IPO rush

Chinese biopharmaceutical firm to list biologics arm in Hong Kong after delisting in New York in 2015. All the signs are it will deliver healthy returns for backers of its privatisation.

Chinese biopharmaceutical firm Wuxi AppTec has taken the first step to relist its assets in Asia, launching a HK$3.6 billion to HK$4 billion $461m to $511 million initial public offering for its biologics division in Hong Kong on Wednesday.

The Wuxi Biologics IPO comes 18 months after its parent was delisted from the New York stock exchange in December 2015. The parent, then known as Wuxi PharmaTech, was taken private through a $3.3 billion management buyout supported by Chinese private equity funds Boyu, Hillhouse and Ally Bridge, as well as Singapore sovereign fund Temasek Holdings and Ping An Insurance.

...

¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team subscription (2-5 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team subscription (2-5 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222